SRPT- A Squeeze In The Making

  Sarepta Therapeutics, Inc. (SRPT)-Nasdaq   Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan Stanley Healthcare Conference on September 10th. We received guidance in April from the FDA that outlined a very clear path-forward, which resulted in a plan […]

SPY – A Quick Look at The Broader Market

SPDR S&P 500 (SPY) –NYSE   Yesterday we got a sharp turn in the SP-500 as the daily chart of the SPY (S&P 500 ETF) drops sharply and breaks down the uptrend channel for the first time after two months of uptrend within the channel. Breaking down the 50-Day moving average as well which was supposed be […]

Tekmira – Is It The Bottom Yet

  Tekmira Pharmaceuticals Corp (TKMR) –Nasdaq   Tekmira is the new “fallen star” after the wild run started Jan 07th, 2014 from $7.66, and reaching the all time high $31.48 mid March. But that was the inflection point as well, the price start dropping fast with no stops or even real technical correction, reaching the support […]

BMY – In The Inflection Point

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years high $57.49 in early March 2014, as investors were anticipating the anti PD-1 data coming at ASCO-2014 and with high expectations for  BMY’s data of […]

RTRX – In a Consolidation Mode

Retrophin, Inc. (RTRX) –Nasdaq   During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation mode. The MACD moving to the positive territory along with the RSI positive momentum as well. the next resistance line is the 50-Day moving average […]

IBB – In the Decision Zone

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as the biotech barometer. And as mentioned in my last report ” IBB – Biotech Sector in The Despondency Point ” the emotions are playing an important role […]

Progenics: Consolidation Ahead of the AdCom

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq   Relistor has been approved by regulatory authorities in the U.S., countries in the E.U., Canada and Australia since 2008 for treatment of OIC in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient. On May 09, 2014 Progenics  announced during the 1Q earnings call an FDA Advisory Committee […]

IBB – Biotech Sector in The Despondency Point

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as the biotech barometer, which has suffered lately from an over exposure. It has been mentioned nonstop on any financial TV programs or investors reports, trying […]

Pfizer – Technical points to watch

Pfizer Inc. (PFE) -NYSE A long awaited date from Pfizer revealed on Sunday April 04, 2014 at the AACR-2014. Pfizer  announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women with […]

IBB – In The Decision Zone

iShares Nasdaq Biotechnology (IBB) -Nasdaq The best indicator for our biotech portfolios are biotechnology indices such as IBB, NBI, XBI or XLV. By looking at the IBB daily chart, we get the whole picture of the latest epic run in the biotech sector during 2013, with a whopping run from 134.21 to 227.06 points, gaining 69.2%, while […]

BMY – Quick Chart Update

Bristol-Myers Squibb Company (BMY)  -NYSE   Interesting price action since September 9th after breaking out the downtrend line around $41.90, we kept watching the chart day after day during the preparation to AASLD reaching the high of $47.90, followed by a price consolidation and forming a flag pattern that we discussed several times through the private […]

ONTX – Looking For The Reversal Pattern

Onconova Therapeutics, Inc. (ONTX) -Nasdaq   Onconova has recently plunged about $19 from the 52-week high at $31.13, reached just a month ago to the current level in mid-$13s and reaching the low of $12.03 today. Surprising given the Phase 3 readout coming up and final results from the Phase-II trial of oral rigosertib in 1st-line Low-Risk […]